Q-omics provides the consensus-scored RYR1 profile across patient tissues and cancer cell-line models. RYR1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RYR1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, RYR1 RNA expression shows 17,486 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, THCA, and HNSC as cancer lineages where RYR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RYR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RYR1 survival associations across molecular data types. RYR1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RYR1 RNA expression–survival associations across cancer types. High RYR1 expression shows unfavorable associations in LAML and UCEC, but favorable associations in UVM, BRCA, SCLC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RYR1 RNA expression.
This table summarizes RYR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RYR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RYR1 shows lower tumor expression in KICH, COAD and BRCA and higher tumor expression in THCA, LIHC and LUSC. The THCA box plot shows higher RYR1 RNA expression in tumor versus normal tissue (log2 FC = +1.879, t-test p < 0.001).
This table shows molecular features associated with RYR1 in patient tissues and cancer cell lines. In patient samples, RYR1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, RYR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
